The Medicines and Healthcare products Regulatory Agency has published a five-year strategy setting out how it intends to adapt medicines and medical-device regulation through 2030. The plan links faster regulatory processes with patient safety, wider use of real-world data, stronger action against illegal products and new oversight arrangements for artificial intelligence.
The agency says its goal is to help people across all four UK nations gain faster access to safe and effective treatments while protecting public health. These are strategic ambitions and delivery commitments, not evidence that new systems have already been introduced or that patients will necessarily receive treatments sooner.
Shorter targets for selected applications
Among the most specific service targets, the MHRA plans to halve the initial-assessment target for qualifying Phase 1 clinical-trial applications to 14 days. Phase 1 studies are early clinical trials, and the target applies to qualifying applications rather than every trial or every stage of review.
The strategy also proposes a higher-value option for developers seeking scientific advice, with a target to reduce the service time from 90 days to 45 days. The agency says it intends to make decisions on generic and biosimilar products faster as well. These commitments concern regulatory processes; they do not guarantee approval, a trial outcome, or a medicine’s availability through the NHS.
For evidence and safety monitoring, the regulator plans to improve access to real-world data from hospitals and genomics, recruit specialist staff and use artificial intelligence to analyse information for possible safety signals. It also intends to work with the Health Data Research Service on real-time surveillance and to improve the collection and use of medical-device data, including traceability through a product’s lifecycle. The strategy presents these as planned capabilities, not proof that a particular safety issue has already been detected.
AI tools and oversight
The MHRA says it will develop an AI-enabled Clinical Trial Protocol Checker. The intended purpose is to help sponsors identify common reasons an application might not be accepted before it is submitted. It is a proposed support tool for the application process, not a clinical decision-maker, diagnostic service or substitute for regulatory review.
The plan also commits to establishing a Centre for AI and Digital Health to clarify regulatory expectations for developers of digital and AI-driven medical devices and medicines. An AI Medicines Development Action Plan is due in 2027. The agency says it will create a modern, adaptive framework for AI as a medical device, while developing its expertise in regulating technologies that can change over time.
Other commitments concern patients and enforcement. The strategy proposes increasing diversity in clinical studies, publishing a Women’s Health Plan and refreshing the agency’s patient and public involvement plan. It also promises substantially greater criminal enforcement capacity against illegal medicines and medical devices, alongside work with online platforms and marketplaces to limit harmful products and misinformation.
Delivery remains the test
The strategy describes a broad programme rather than a single rule change. It combines operational targets with longer-term work on evidence, technology, patient involvement and international regulatory cooperation. Some elements have stated milestones, including the 2027 AI plan, while others are described as aims without a detailed timetable in the announcement.
For patients, the practical effect will depend on whether the agency can deliver the promised services while maintaining standards for safety, quality and effectiveness. Faster assessment targets alone do not establish that a treatment works, that a device is safe for a particular person, or that clinical access will follow immediately. Those questions still depend on evidence, regulatory decisions and relevant health-service processes.
The MHRA frames the strategy as a response to advances in personalised medicine, cell and gene therapies, diagnostics and AI. Its central challenge is to adapt how evidence is assessed, and safety is monitored without treating speed as a replacement for scrutiny. The commitments set out the direction of travel; their impact will become clearer as specific services and frameworks are developed.
